AstraZeneca's New Lung Treatment Could Become Market Leader — Market Talk
AstraZeneca's new drug for chronic obstructive pulmonary disease could become a market leader if it proves to be effective across all patient groups, Berenberg analysts say in a research note. Initial trial results released by the U.K. drugmaker earlier this year showed the drug, tozorakimab, deliv…